Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics adds two directors, expanding its board from seven to nine

Neutral Impact 2 of 5 leadership Written later

Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors effective October 19, 2026, increasing the Board from seven to nine members. The filing says both were granted stock options and restricted stock units under the company's non-employee director compensation program, and the Board determined both are independent under Nasdaq rules.

Key points

  • Kristine Peterson joins as a Class I director (term to 2027 annual meeting) and on the Audit Committee.
  • Lonnel Coats joins as a Class II director (term to 2028 annual meeting) and on the Compensation Committee.
  • Each received an option to purchase 16,600 shares and a restricted stock unit award covering 12,400 shares, vesting over three years.

The filing

CompanyMineralys Therapeutics, Inc. (MLYS)
Form8-K, current report
Filed with the SECOct 19, 2026, 4:37 PM ET
Accession number0001933414-26-000125

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.